其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Sodium Stearate CAS Registry Number: 822-16-2 硬脂酸钠

CAS Name: Stearic acid sodium salt
Literature References: Approx C18H35NaO2. Usually contains sodium palmitate.

Potassium Stearate CAS Registry Number: 593-29-3 硬脂酸钾

CAS Name: Stearic acid potassium salt
Literature References: Approx KC18H35O2. The article of commerce contains a considerable proportion of palmitate.

Sodium Pyroantimonate CAS Registry Number: 10049-22-6

Additional Names: Sodium antimonate
Literature References: Approx Na2H2Sb2O7.

Sulfur Iodide CAS Registry Number: 1312-15-8

Additional Names: Iodosulfane
Literature References: Approx SI. Obtained by fusing together 4 parts iodine with 1 part sulfur. It probably contains free iodine as well as free sulfur.

Anastrozole CAS Registry Number: 120511-73-1 阿那曲唑

CAS Name: a,a,a',a'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Additional Names: 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)Trademar...
Literature References: Aromatase inhibitor. Prepn: P. N. Edwards, M. S. Large, EP 296749; eidem, US 4935437 (1989, 1990 both to ICI). Reviews of pharmacology, clinical pharmacokinetics: P. V. Plourde et al., Breast Cancer Res. Treat. 30, 103-111 (1994); idem et al., J. Steroid Biochem. Mol. Biol. 53, 175-179 (1995). Clinical trial in advanced breast cancer: A. U. Buzdar et al., Cancer 79, 730 (1997).

Aminoglutethimide CAS Registry Number: 125-84-8 氨鲁米特

CAS Name: 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione
Additional Names: 2-(p-aminophenyl)-2-ethylglutarimide; 3-ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
Trademarks: Cytadren (Novartis);...
Literature References: Aromatase inhibitor; also blocks adrenal steroidogenesis. Formerly used as anticonvulsant. Prepn: K. Hoffmann, E. Urech, US 2848455 (1958 to Ciba). Mass spectrum: G. Ruecker, G. Bohn, Arch. Pharm. 302, 204 (1969). Resolution and abs config of antipodes: N. Finch et al., Experientia 31, 1002 (1975). Comprehensive description: H. Y. Aboul-Enein, Anal. Profiles Drug Subs. 15, 35-69 (1986). Review of pharmacology and clinical use in Cushing's disease and breast cancer: R. J. Santen, R. I. Misbin, Pharmacotherapy 1, 95-120 (1981); in prostate cancer: K. A. Havlin, D. L. Trump, Cancer Treat. Res. 39, 83-96 (1988).

Etretinate CAS Registry Number: 54350-48-0 依曲替酯

CAS Name: (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid ethyl esterTrademarks: Tegison (Roche); Tigason (Roche)
Percent Composition: C 77.93%, H 8.53%, O ...
Literature References: Aromatic analog of retinoic acid, q.v. Prepn: W. Bollag et al., DE 2414619; eidem, US 4105681 and US 4215215 (1974, 1978, 1980 all to Hoffmann-La Roche). Effects on skin metabolism: W. P. Raab, B. M. Gmeiner, Arch. Dermatol. Res. 256, 247 (1976). Toxicity study in organ culture: D. R. Bard, I. Lasnitzki, Br. J. Cancer 35, 110 (1977). Pharmacokinetics: R. Haenni, Dermatologica 157, Suppl, 5 (1978). Mutation study: H. J. Juhl et al., Mutat. Res. 58, 317 (1978). HPLC determn in plasma: R. Haenni et al., J. Chromatogr. 162, 615 (1979). Toxicology, carcinogenicity and teratogenicity study: J. J. Kamm, J. Am. Acad. Dermatol. 6, 652 (1982). Clinical evaluation in psoriatic arthritis: M. L. Ciompi et al., Int. J. Tissue React. 10, 25 (1988). Review: H. Mayer et al., Experientia 34, 1105-1119 (1978). Review of pharmacology and therapeutic efficacy: A. Ward et al., Drugs 26, 9-43 (1983); of clinical pharmacology: A. Vahlquist, O. Rollman, Dermatologica 175, Suppl. 1, 20-27 (1987). Book: The Retinoids Vol. 1-2, M. B. Sporn et al., Eds. (Academic Press, New York, 1984).

Motretinide CAS Registry Number: 56281-36-8 毛替垂尼

CAS Name: (all E)-N-Ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenamide
Additional Names: 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraen-1-oic ...
Literature References: Aromatic analog of retinoic acid, q.v. Prepn: W. Bollag et al., DE 2414619; eidem, US 4215215 (1974, 1980 both to Hoffmann-La Roche). Description of properties: idem, Chemotherapy 21, 236 (1975). 13C-NMR study: G. Englert, Helv. Chim. Acta 58, 2367 (1975). Pharmacology: L. J. Wilkoff et al., Cancer Res. 36, 964 (1976); S. S. Shapiro et al., ibid. 3702. Inhibitory effect on radiation-induced neoplasms: L. Harisiades et al., Nature 274, 486 (1978). Use in treatment of acne: K. Nordin et al., Dermatologica 162, 104 (1981).

Myristicin CAS Registry Number: 607-91-0 肉豆蔻醚

CAS Name: 4-Methoxy-6-(2-propenyl)-1,3-benzodioxole
Additional Names: 5-allyl-1-methoxy-2,3-(methylenedioxy)benzene
Percent Composition: C 68.74%, H 6.29%, O 24.97%
Literature References: Aromatic ether extracted from nutmeg, parsley, carrots. Isoln from nutmeg, Myristica fragrans Houtt., Myristicaceae and characterization: F. B. Power, A. H. Salway, J. Chem. Soc. 91, 2037 (1907); A. T. Shulgin, Nature 197, 379 (1963); from carrots, Daucus carota L., Umbelliferae: S. G. Yates, R. E. England, J. Agric. Food Chem. 30, 317 (1982); from parsley, Petroselinium hortense Hoffman, Umbelliferae: M. Balogh et al., Herba Hung. 17, 39 (1978), C.A. 91, 2543e (1979). Synthesis: V. M. Trikojus, D. E. White, Nature 144, 1016 (1939); F. Dallacker, R. Sluysmans, Monatsh. Chem. 100, 560 (1969). HPLC sepn: L. W. Wulf et al., J. Chromatogr. 161, 271 (1978); A. W. Archer, ibid. 438, 117 (1988). GC-MS study: G. M. Sammy, W. W. Nawar, Chem. Ind. 1968, 1279. MS-MS study of nutmeg extract: D. V. Davis, R. G. Cooks, J. Agric. Food Chem. 30, 495 (1982). Possible psychotropic properties: A. T. Shulgin, Nature 210, 380 (1966).

IPTG CAS Registry Number: 367-93-1 异丙基-β-D-硫代半乳糖苷(IPTG)

CAS Name: 1-Methylethyl 1-thio-b-D-galactopyranoside
Additional Names: isopropyl b-D-thiogalactopyranoside
Percent Composition: C 45.36%, H 7.61%, O 33.57%, S 13.46%
Literature References: Artificial, slow-hydrolyzing inducer of the lactose (lac) operon. Prepn: B. Helferich, D. Türk, Ber. 89, 2215 (1956); U. Carlsson et al., Protein Eng. 4, 1019 (1991). Induction of b-galactosidase: V. Paces et al., Collect. Czech. Chem. Commun. 38, 2983 (1973). Binding to b-D-galactosidase: C. K. De Bruyne, M. Yde, Carbohydr. Res. 56, 153 (1977). Concentration effects on lac operon induction in E. coli: S. Cho et al., Biochem. Biophys. Res. Commun. 128, 1268 (1985). Effect of lactose permease on induction by IPTG: L. H. Hansen et al., Curr. Microbiol. 36, 341 (1998).